Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial
Seung-Jun Lee,Jin-Bae Lee,Tae-Hyun Yang,Woong Chol Kang,Jong-Young Lee,Yong-Joon Lee,Sung-Jin Hong,Chul-Min Ahn,Jung-Sun Kim,Byeong-Keuk Kim,Young-Guk Ko,Bum-Kee Hong,Donghoon Choi,Junghan Yoon,Yangsoo Jang,Myeong-Ki Hong,H M Kwon,J-Y Kim,P K Min,Y W Yoon,B K Lee,S-J Rim,E-Y Choi,P C Oh,K S Kim,J Y Choi,J K Ryu,C Y Kim,H-J Cho,M-S Ahn,S G Ahn,J-W Lee,J-W Son,H-J Yoon,C H Lee,J Hwang,Y-K Cho,S-H Hur,S Han,C-W Nam,H Kim,H-S Park,I-C Kim,Y-H Cho,H-J Jeong,J-H Kim,C Lim,Y Suh,E S Hwang,J H Lee,S Y Lee,S U Kwon,S-Y Kim,K-H Park,H K Kim,
DOI: https://doi.org/10.1093/ageing/afae132
2024-07-01
Age and Ageing
Abstract:Abstract Background The optimal statin treatment strategy that is balanced for both efficacy and safety has not been clearly determined in older adults with coronary artery disease (CAD). Methods In the post hoc analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting statin therapy versus intensity-based statin therapy in patients with coronary artery disease) trial, the impact between a treat-to-target strategy versus a high-intensity statin therapy strategy was compared in older adults (aged 75 years or older). The goal of treat-to-target low-density lipoprotein cholesterol (LDL-C) level was 50–70 mg/dl. The primary endpoint comprised the three-year composite of all-cause death, myocardial infarction, stroke or coronary revascularisation. Results Among 4,400 patients with CAD enrolled in the LODESTAR trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and risk factors for atherosclerosis were more frequently observed in older adults than in younger population (<75 years old). Among these older adults with CAD, the prescription rate of high-intensity statin was significantly lower in the treat-to-target strategy group throughout the study period (P < 0.001). The mean LDL-C level for three years was 65 ± 16 mg/dl in the treat-to-target strategy group and 64 ± 18 mg/dl in the high-intensity statin group (P = 0.34). The incidence of primary endpoint occurrence was 10.9% in the treat-to-target strategy group and 12.0% in the high-intensity statin group (hazard ratio 0.92, 95% confidence interval 0.61–1.38, P = 0.69). Conclusions High-intensity statin therapy is theoretically more necessary in older adults because of worse clinical outcomes and greater number of risk factors for atherosclerosis. However, the primary endpoint occurrence with a treat-to-target strategy with an LDL-C goal of 50–70 mg/dl was comparable to that of high-intensity statin therapy and reduced utilisation of a high-intensity statin. Taking efficacy as well as safety into account, adopting a tailored approach may be considered for this high-risk population. Trial Registration ClinicalTrials.gov, NCT02579499.
geriatrics & gerontology,gerontology